Fresh Equities
ASX:RCE

ASX:RCE

RECCE PHARMACEUTICALS LTD

4W AVG VOLUME
423.85k
Data provided by Weblink | as of close 2020-01-24
4W AVG TURNOVER
$147.53k

RECCE PHARMACEUTICALS LTD has not announced any current capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise
$100k - $250k
Investors Interested in Next Raise
10 - 25
How Fresh Equities Works
Authentication

1. Create Account

Complete your onboarding digitally in less than 3 minutes.

Authentication

2. View Terms

View the full term sheet for the capital raise.

Authentication

3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

Loading...


Company Overview

Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. RCE's portfolio of antibiotic therapies seek to address health threats posed by drug resistant bacteria. Their lead candidate RECCE®327 is designed as abroad-spectrum antibiotic, formulated using synthetic polymer technology to treat bacterial sepsis (blood poisoning) and other bacterial infections, including superbugs.

Type

Listed Company

GICS Sub-industry

Pharmaceuticals

Head Office

Level 36, Gateway, 1 Macquarie Pl, Sydney NSW 2000, Australia

Pharmaceuticals
Health Care
Biotech & Health

Price Chart


Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.

Fresh Equities does not have RECCE PHARMACEUTICALS LTD quarterly cash flows data.


Directors


Announcements

All
All Time
    Cleansing Statement on 16 January 2020

    Issued Capital

    Appendix 2A on 16 January 2020

    Issued Capital

    Change of Director's Interest Notice on 20 December 2019

    Shareholder Details

    Change of Director's Interest Notice on 19 December 2019

    Shareholder Details

    Cleansing Statement on 19 December 2019

    Issued Capital

    Appendix 3B on 19 December 2019

    Issued Capital

    Corporate Presentation - December 2019 on 4 December 2019

    Periodic Reports

    Constitution on 29 November 2019

    Company Administration

  • Positive Data for RECCE 327 in MRSA Burns Wound Infection on 26 November 2019

    Stock Exchange Announcement

  • Results of Meeting on 25 November 2019

    Notice Of Meeting

    Load More

News

Fresh Equities does not have RECCE PHARMACEUTICALS LTD news data.